HMGB2 and hepatocellular carcinoma: scRNA-seq for HCC lesions scheduled to neoadjuvant anti–PD-1 monotherapy was performed to evaluate the role of HMGB2+ CD8+ T cells in ICI efficacy from our previous study (26).